BGI

I'm in a weird spot both recognizing Chinese stocks are cheap on fundamentals, but also a bear market or global recession isn't going to be good for them either. Much more interested in owning something like CGN with a 5 percent dividend yield, than Alibaba or Baidu that is responsible for the pop in FXI today.

The impetus for the move today is the government signaling it will inflate the currency and restart the housing bubble. Interest rates are already falling in China and the 10-year yield is below 3 percent.

Bloomberg: China’s Pledge to Lift Consumption Sparks Debate on Cash Handouts

iFeng: 利好来了！公积金贷款利率下调

BGI Genomics

Down to less than 30x earnings assuming earnings don't crater, though they could along with the everything else. Still, looking through to the next bull cycle...

Chinese Biotech Looks Weak Too

Global markets.

BGI Genomics

Cold War Goes Genetic: Illumina Sues BGI Genomics

Caixin: Chinese DNA Sequencing Firm BGI Faces Legal Battle with Illumina

BGI’s subsidiary BGI Europe was sued by Illumina Inc. in Denmark on alleged patent infringement last week. The complaint alleged BGI's sequencing products and related sequencing chemistry reagents infringe on Illumina's European patent.

The case followed another infringement suit filed by Illumina in Germany against another BGI subsidiary, Latvia MGI Tech, in March.

ChiNext Analog

BGI Genomics rallied to a new high today.

BGI Genomics Limit Down on Friday

华大基因 (300676)

BGI Genomics Limit Up Streak Ends

BGI Genomics didn't open limit up today. Shares are up 0.5 percent at the moment. Volume was 27 million on Wednesday. Current volume is 10 million shares. Shares could rally and finish limit up today, but it looks like the streak ends at an impressive 18 days, not counting the IPO day which saw shares jump more than 10 percent.

MSCI Warns on Share Halts, BGI Limit Up Again

Companies that halt shares for 50 days or more will be removed from the MSCI Emerging Markets Index for at least 12 months.

CNBC: MSCI warns Chinese companies with suspended shares they could get dropped from the emerging markets index

BGI was limit up again on Monday giving it a valuation of $3 billion. As a "castle in the sky" stock it is still very under "valued."

BGI Genomics Limit Up Nine Consecutive Days

Still has a ways to go before it catches Baofeng's streak of 28 days. Baofeng would resume it's limit-up run, ending at 35 of 36 days before being halted. Shares are down more than 80 percent from their 2015 peak.

华大基因 (300676)